HuGAL-F2 is a humanized monoclonal antibody targeting human basic fibroblast growth factor (bFGF/FGF2). FGF2 is a critical factor in tumor angiogenesis, exerting its effects by binding to and activating FGFRs, which possess receptor tyrosine kinase activity. HuGAL-F2 functions by specifically binding to and neutralizing extracellular FGF2, blocking its interaction with FGFRs and directly inhibiting endothelial cell proliferation, migration, and tube formation mediated by this pathway. Featuring a huIgG2 heavy chain and a hu-kappa light chain, this antibody is a significant tool for researching solid tumor angiogenesis and tissue fibrosis.